A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 1×
“The estimates for dementia prevalence vary based on geographic location and diagnostic criteria used, but it is thought that at least 5 % of people over the age of 60 years live with dementia, and the total number of these cases is expected to double every 20 years [4].”
BackgroundBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“Over half of community-dwelling and roughly 90 % of institutionalized Alzheimer’s patients have dementia rated as moderate to severe, so further research on this population is clearly needed [55, 162].”
BackgroundMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 1×
“Mixed Alzheimer’s disease and vascular dementia is common, accounting for approximately 25 % of all dementia cases [29].”
BackgroundCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“A few small studies have shown some minimal cognitive benefits of ChEIs in the treatment of MCI [56, 82–84], but pooled data analyses of the trials show that there is no significant difference in progression to dementia, nor in global, cognitive, or neuropsychiatric outcomes [7, 85, 86].”
BackgroundEpidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · cited 1×
“Alzheimer’s disease is the most common cause, accounting for roughly 50–70 % of all dementia cases [22].”
BackgroundMcShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892 · cited 1×
“9 points by 12 weeks that did not significantly change in the second randomization period for the duration of the trial [100].”
BackgroundOrgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539 · cited 1×
“Memantine treatment in vascular dementia for 6 months showed minimal improvement in cognitive status (approximately 2 points on the ADAS-cog scale) without a significant effect on global outcomes or neuropsychiatric scores [94, 154, 155].”
BackgroundKavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study
Bachman, D. L., Wolf, P. A., Linn, R. T., Knoefel, J. E., Cobb, J. L., Belanger, A. J., White, L. R., & D'Agostino, R. B. (1993) · Neurology · doi:10.1212/wnl.43.3_part_1.515 · Cited by 470
Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006504.pub2 · Cited by 418
Wilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381
White, H., Pieper, C., & Schmader, K. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb04537.x · Cited by 323 · cited 1×
“Weight loss can be quite detrimental in the frail elderly population and has been associated with decreased quality of life, functional decline, institutionalization, and increased mortality [126–130].”
BackgroundInitiative, F. T. A. D. N., Skinner, J., Carvalho, J. O., Potter, G. G., Thames, A., Zelinski, E., Crane, P. K., & Gibbons, L. E. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9166-3 · Cited by 151
The overlap between syncope and falls in the elderly
Shaw, F. E., & Kenny, R. A. (1997) · Postgraduate Medical Journal · doi:10.1136/pgmj.73.864.635 · Cited by 137 · cited 1×
“However, most falls are not due to syncope and many do not result in injury [138–140].”
BackgroundMemantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias
Molinuevo, J. L., Lladó, A., & Rami, L. (2005) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/153331750502000206 · Cited by 125 · cited 1×
“functions of glutamate in learning and memory [68–71].”
BackgroundThe benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease
Voisin, T., & Vellas, B. (2009) · Drugs & Aging · doi:10.2165/0002512-200926020-00005 · Cited by 89 · cited 3×
“In moderate dementia, the individual begins to lose independence and conversational skills and may forget significant personal information [56, 63].”
BackgroundTrinh, N.-H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003) · JAMA · doi:10.1001/jama.289.2.210 · Cited by 37
Cited by
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
Radd-Vagenas, S., Duffy, S. L., Naismith, S. L., Brew, B. J., Flood, V. M., & Fiatarone Singh, M. A. (2018) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqx070 · Cited by 176
Zhu, H.-Y., Hong, F.-F., & Yang, S.-L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094540 · Cited by 84
Na, R., Yang, J.-H., Yeom, Y., Kim, Y. J., Byun, S., Kim, K., & Kim, K. W. (2019) · Psychiatry Investigation · doi:10.30773/pi.2019.02.11.2 · Cited by 70
“330 Psychiatry Investig 2019;16(5):325-335 NPI for People with Moderate to Severe Dementia”
BackgroundInfluential
Metadata
- Authors
- Buckley, J. S., & Salpeter, S. R.
- Venue
- Drugs & Aging
- Published
- 2015-05-05
- Volume
- 32
- Issue
- 6
- Pages
- 453-467
- ISSN
- 1170-229X (ISSN-L)
- 1179-1969
- OpenAlex
- W1720436125
- Cited by
- 167
- References
- 25
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.